Management of Carbapenemase-Resistant Organism Infections

Immediate Actions After Receiving Test Results

Upon receiving carbapenemase resistance testing results, immediately initiate infectious disease consultation and tailor antimicrobial therapy based on the specific carbapenemase type identified, as different enzyme classes require distinct treatment strategies 1, 2
Infectious disease consultation is strongly recommended for all MDRO infections to optimize treatment selection and improve clinical outcomes 3
This consultation should occur within 24 hours of receiving carbapenemase testing results 3

Rapid molecular testing (RT-PCR or Carba NP) should be used to identify the specific carbapenemase family, as these tests are 98-100% sensitive and specific with <3 hour turnaround time 1, 4, 5
Different carbapenemase types require different treatment approaches: KPC responds to ceftazidime-avibactam and meropenem-vaborbactam, while metallo-β-lactamases (NDM, VIM) do not 2, 6
First-line treatment for KPC-producing Enterobacterales (bloodstream infections) is ceftazidime-avibactam 2.5 g IV q8h infused over 3 hours 3, 6
Alternative first-line treatment for KPC-producing Enterobacterales (bloodstream infections) is meropenem-vaborbactam 4 g IV q8h 3, 6
Polymyxin-based combination therapy is recommended for metallo-β-lactamase producers (NDM, VIM, IMP) as ceftazidime-avibactam and meropenem-vaborbactam are ineffective against metallo-β-lactamases 2, 3

Ceftazidime-avibactam 2.5 g IV q8h is effective against OXA-48-like carbapenemases 2
For urinary tract infections (cUTI) related to CRE, ceftazidime-avibactam 2.5 g IV q8h is recommended 3
For respiratory sources of bacteremia, meropenem-vaborbactam may be preferred due to better epithelial lining fluid concentrations 6

Consider synergy testing when drug choices are limited, such as poor response to monotherapy after 48-72 hours, no effective options on conventional susceptibility testing, or in critically ill patients 4, 5, 8
Checkerboard microdilution method is the gold standard for synergy testing, providing quantitative fractional inhibitory concentration (FIC) indices 8

Prolonged infusion of β-lactams is recommended for pathogens with high MIC to maximize time above MIC 3
Administer meropenem as 3-hour infusion rather than standard 30-minute infusion 3

Minimum 7-14 days of appropriate therapy is recommended for uncomplicated bacteremia 6
14-21 days of therapy is typically required for complicated bacteremia with metastatic foci 6
Continue therapy at least until neutrophil recovery (ANC >500 cells/mm³) in neutropenic patients 6

Implement strict contact precautions immediately upon identification of carbapenemase-producing organisms 9
Perform point-prevalence surveys with rectal swabs or stool specimens for all patients on the same unit 9

Daily clinical assessment for treatment response is essential 6
Monitor for adverse effects: nephrotoxicity with polymyxins and aminoglycosides, seizures with carbapenems (especially meropenem), thrombocytopenia 3
Serum levels of aminoglycosides and vancomycin must be monitored closely to decrease risk of renal failure 7

Avoid tigecycline monotherapy for CRAB pneumonia—it is associated with poor outcomes 3
Combination therapy is generally preferred over monotherapy for severe carbapenem-resistant infections 3, 4, 5
Do not delay starting novel agents if available while waiting for synergy testing results—start immediately in critically ill patients 8